Research Progress on the Ability of Astragaloside IV to Protect the Brain Against Ischemia-Reperfusion Injury

Kang, Xianhui; Su, Shuyue; Hong, Wandong; Geng, Wujun; Tang, Hongli

doi:10.3389/fnins.2021.755902

Cited by 16 publications

(8 citation statements)

References 78 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Huangqi is a traditional Chinese Qi-tonifying herb. Astragaloside is one of the active ingredients of Huangqi, which has the effects of improving the permeability of the blood-brain barrier, reducing the free radical content of ischemic brain tissue, and inhibiting inflammatory mediators (Kang et al, 2021). Danshen has the effect of removing blood stasis, relieving pain, clearing the heart, and dispelling troubles.…”

Section: Introductionmentioning

confidence: 99%

Investigation into the potential mechanism and molecular targets of Fufang Xueshuantong capsule for the treatment of ischemic stroke based on network pharmacology and molecular docking

Wang

Wang³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Fufang Xueshuantong (FFXST) capsule is a traditional Chinese medicine (TCM) preparation used to activate blood circulation, resolve stasis, benefit qi, and nourish yin in clinical practice. However, its potential mechanism and molecular targets after ischemic stroke (IS) have not been investigated. The aim of this research was to investigate the molecular mechanisms of FFXST in the treatment of IS based on network pharmacology and molecular docking. We used the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) to collect candidate compounds of four herbs in FFXST; disease-related differential genes were screened using the Gene Expression Omnibus (GEO) database, and a compound-disease network was created using Cytoscape 3.8.2 software. The topological analysis of the protein-protein interaction (PPI) network was then created to determine the candidate targets of FFXST against IS. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted using the clusterProfiler package in R. The gene-pathway network of FFXST against IS was created to obtain the key target genes. Molecular docking was used to validate the core targets using AutoDock Vina 1.1.2. A total of 455 candidate compounds of FFXST and 18,544 disease-related differential genes were screened. Among them, FFXST targets for IS treatment had 67 active compounds and 10 targets in the PPI network related to STAT1, STAT3, and HIF1A. The biological processes of GO analysis included the regulation of reactive oxygen species metabolic process, cellular response to chemical stress, regulation of angiogenesis, regulation of vasculature development, positive regulation of cytokine production, and response to oxidative stress. The KEGG enrichment analysis showed that Kaposi sarcoma-associated herpesvirus infection, microRNAs in the cancer signaling pathway, Th17 cell differentiation, and HIF-1 signaling

show abstract

Section: Introductionmentioning

confidence: 99%

Investigation into the potential mechanism and molecular targets of Fufang Xueshuantong capsule for the treatment of ischemic stroke based on network pharmacology and molecular docking

Wang

Wang³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Pharmacological studies have attributed antiaging, antiapoptosis, antioxidation, energy metabolism-regulating and autophagy actions to astragaloside IV [15,16]. It has been reported to reduce cerebral I/R injury [4,5] by an unknown mechanism.…”

Section: Discussionmentioning

confidence: 99%

“…The traditional Chinese medicine, Astragalus membranaceus, of which Astragaloside IV is a major component, has been used to treat I/R injury. Astragaloside IV has been found to reduce cerebral infarct volume, protect the integrity of the blood-brain barrier, inhibit apoptosis and stimulate energy metabolism to reduce cerebral I/R injury [4,5]. However, specific mechanisms of action are not clear.…”

Section: Introductionmentioning

confidence: 99%

Astragaloside IV ameliorates cerebral ischemia-reperfusion injury via upregulation of PKA and Cx36

Liu¹,

Wang²,

Tang³

et al. 2022

NeuroReport

View full text Add to dashboard Cite

ObjectivesTo determine the effects of astragaloside IV on cerebral ischemic-reperfusion injury in rats and to explore underlying mechanisms of brain protection.Methods Sixty Sprague-Dawley rats were randomized into four groups: Sham, cerebral ischemia-reperfusion (I/R group), I/R+astragaloside IV (I/R+AST-IV group) and I/R+astragaloside IV+PKA kinase inhibitor H-89 (I/R+AST-IV+H-89 group). All I/R rats were subjected to 2 h cerebral ischemia, followed by 24 h reperfusion and scored for neurobehavior. Cerebral infarct volume, pathomorphological changes and brain apoptosis, in addition to changes in expression of Cx36, PKA, Bax and Bcl-2 proteins, were assessed. ResultsAstragaloside IV treatment reduced neurobehavioral score and percentage volume of cerebral infarct, reducing pathomorphological injury and brain apoptosis. Expressions of Cx36 and PKA protein were increased and the Bax/Bcl-2 ratio decreased. All astragaloside IV effects were reversed by the PKA inhibitor and H-89.Conclusions Astragaloside IV attenuated cerebral I/R injury in rats by increasing Cx36 and PKA protein expression and reducing the Bax/Bcl-2 ratio. NeuroReport

show abstract

“…Astragaloside contains four subtypes (I–IV), among which astragaloside IV has the best biological activity ( 31 , 32 ). Due to the multiple target advantages of astragaloside IV, its preparation is widely used in the adjuvant treatment of cardiovascular and cerebrovascular diseases ( 33 , 34 ). It has the effects of improving immunity, reducing stress reaction, antivirus, anti-inflammation, analgesia, organ protection and promoting metabolism ( 31 , 32 ).…”

Section: Discussionmentioning

confidence: 99%

Antihypertension effect of astragaloside IV during cerebral ischemia reperfusion in rats

Shen

Meng

et al. 2022

Mol Med Rep

View full text Add to dashboard Cite

Stroke is one of the leading causes of death from diseases. When the blood supply to the brain tissue is interrupted, neuronal core death occurs due to the lack of glucose and oxygen in min. Blood pressure lowering after ischemic stroke was proven to be an effective strategy to achieve neurovascular protection and reduce the risk of recurrent stroke. Astragaloside IV is a pure small molecular compound isolated from Radix Astragali, and it is well documented that astragaloside IV has neuroprotective effect on cerebral ischemia reperfusion (CIR) injury through many mechanisms, including antioxidant, anti-inflammatory and anti-apoptotic. The present study adopted mean arterial pressure (MAP) monitoring, neurological scoring, 2,3,5-triphenyltetrazolium chloride staining, enzyme-linked immuno-sorbent assay, western blotting and other experimental methods to investigate the effect of astragaloside IV on systemic blood pressure during CIR in a middle cerebral artery occlusion animal model. It was demonstrated that astragaloside IV pretreatment significantly alleviated CIR injury as previously reported. In addition, the elevation of MAP during CIR was significantly inhibited by astragaloside IV administration. Moreover, it was revealed that the expression of Na + -K + -2Clcotransporter isoform 1 in the hypothalamus was inhibited and the subsequent synthesis of vasopressin was reduced by astragaloside IV pretreatment in the CIR animal model. In conclusion, astragaloside IV may alleviate CIR injury partially by lowering systemic blood pressure.

show abstract

Research Progress on the Ability of Astragaloside IV to Protect the Brain Against Ischemia-Reperfusion Injury

Cited by 16 publications

References 78 publications

Investigation into the potential mechanism and molecular targets of Fufang Xueshuantong capsule for the treatment of ischemic stroke based on network pharmacology and molecular docking

Investigation into the potential mechanism and molecular targets of Fufang Xueshuantong capsule for the treatment of ischemic stroke based on network pharmacology and molecular docking

Astragaloside IV ameliorates cerebral ischemia-reperfusion injury via upregulation of PKA and Cx36

Antihypertension effect of astragaloside IV during cerebral ischemia reperfusion in rats

Contact Info

Product

Resources

About